地拉罗司吃多长时间能见效？

(Enrig) How long does it take to take effect? Deferasirox (Enrige) is used to treat chronic iron overload caused by frequent blood transfusions (monthly administration of concentrated red blood cells ≥7 mL/kg) in patients with β-thalassemia older than 6 years of age.

Obvious effects can be seen after taking Deferasirox (Enrige) continuously for one month. The recommended starting daily dose of deferasirox (Enrige) is 20 mg/kg. For patients who receive monthly transfusions of more than 14 mL/kg of packed red blood cells (ie, more than 4 units/month in adults) and who need to reduce excess iron exposure, a starting dose of 30 mg/kg/day may be considered. For patients who receive monthly transfusions of less than 7 mL/kg of packed red blood cells (i.e., less than 2 units/month in adults) and who need to maintain body iron balance, a starting dose of 10 mg/kg/day may be considered. In patients who have already responded well to deferoxamine therapy, an initial dose equivalent to half the deferoxamine dose may be considered. Take Deferasirox on an empty stomach at least 30 minutes before meals, once a day, preferably at the same time every day.

Deferasirox (Enreg) dose adjustment:

Myelosuppression: Interrupt treatment; may restart once cause of cytopenias is identified; Contraindicated if platelet count <50,000/mm; Cutaneous Toxicity: Rash (severe): Interrupt treatment; may reintroduce at lower doses (with future dose escalation) and short-term oral corticosteroids. Serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme): Stop and evaluate. Gastrointestinal: Discontinue treatment for suspected gastrointestinal ulceration or bleeding. Hearing loss or visual impairment: Consider dose reduction or treatment interruption.

The above is the taking guide and dosage adjustment of (Enrige) provided by our medical companion travel overseas medical consulting service company. Patients must read the instructions carefully and take the medicine on time.

Recommended related hot articles: /newsDetail/75860.html